FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
Dickran Kazandjian(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Meredith Libeg(United States Food and Drug Administration), Patricia Keegan(Center for Drug Evaluation and Research), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kun He(Hebei Medical University), Sirisha L. Mushti(United States Food and Drug Administration)
Cited by 478
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k